Skip to content

Prevalence of Bronchiectasis in COPD Patients

Prevalence of and Prognostic Impact of Bronchiectasis in COPD Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04101448
Enrollment
100
Registered
2019-09-24
Start date
2019-09-30
Completion date
2020-09-30
Last updated
2019-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchiectasis, Chronic Obstruct Airways Disease, Prognosis

Keywords

Bronchiectasis, COPD, Prevalence, Prognosis

Brief summary

The identification of bronchiectasis in COPD has been defined as a different clinical COPD phenotype with greater symptomatic severity, more frequent chronic bronchial infection and exacerbations, and poor prognosis. A causal association has not yet been proven, but it is biologically plausible that COPD, and particularly the infective and exacerbator COPD phenotypes, could be the cause of bronchiectasis without any other known etiology, beyond any mere association or comorbidity.

Detailed description

The relationship between bronchiectasis and COPD has generated several questions. Is there any real increased prevalence of bronchiectasis in patients with COPD? Does the presence of bronchiectasis have an impact on the clinical characteristics, prognosis, or response to treatment in COPD, to the extent that it can be considered a distinct clinical phenotype? Should bronchiectasis in patients with COPD be seen as merely a comorbidity, or as a consequence of the disease's natural history? Is there a causal relationship between COPD and bronchiectasis? If this is the case, what are the pathophysiological mechanisms responsible for this relationship? And, finally, what is the role of chronic bronchial infection and exacerbations in this relationship?

Interventions

OTHERprevalence

percentage of bronchectasis in COPD and its effect as prognostic measure

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years

Inclusion criteria

* COPD patients based on GOLD 2019 criteria, stable or in exacerbation

Exclusion criteria

* acute pneumonia within 2 months * malignancy * congenital bronchiectasis ( immobile cilia syndrome, Kartagnar syndrome). * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Prevalence of Bronchiectasis in COPD1 yearpercentage of bronchiectasis diagnosed by CT chest in COPD patients

Secondary

MeasureTime frameDescription
impact of bronchiectasis on COPD exacerbations1 yearnumber of exacerbations treated in or out of hospitals
impact of bronchiectasis on COPD hospitalization1 yearnumber of hospital admissions with acute exacerbations
impact of bronchiectasis on COPD intensive care admission1 yearnumber of admissions in respiratory ICU and need for mechanical or non invasive ventilation

Countries

Egypt

Contacts

Primary ContactAliae Mohamed-Hussein
aliaehussein@gmail.com01222302352

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026